Kompozisyon:
Uygulama:
Tedavide kullanılır:
Militian Inessa Mesropovna tarafından tıbbi olarak gözden geçirilmiştir, Eczane Son güncelleme: 08.04.2022
Dikkat! Sayfadaki bilgiler sadece sağlık profesyonelleri içindir! Bilgi kamu kaynaklarında toplanır ve anlamlı hatalar içerebilir! Dikkatli olun ve bu sayfadaki tüm bilgileri tekrar kontrol edin!
Aynı bileşenlere sahip en iyi 20 ilaç:
Treatment of moderate to severe pain.
Adults
ULTRAM® (tramadol hydrochloride) is indicated for the management of moderate to moderately severe pain in adults.
Geriatrics ( > 65 Years of Age)
Healthy elderly subjects aged 65 to 75 years administered tramadol have plasma concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. ULTRAM® should be administered with greater caution in patients older than 75 years, due to the greater potential for adverse events in this population (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).
Pediatrics ( < 18 Years of Age)
The safety and effectiveness of ULTRAM® have not been studied in the pediatric population. Therefore, use of ULTRAM® tablets is not recommended in patients under 18 years of age.
Treatment of moderate to severe pain.
These tablets are indicated in adults and adolescents aged 12 years and above.
Orozamudol is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
Adults
Orozamudol® (tramadol hydrochloride) is indicated for the management of moderate to moderately severe pain in adults.
Geriatrics ( > 65 Years of Age)
Healthy elderly subjects aged 65 to 75 years administered tramadol have plasma concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. Orozamudol® should be administered with greater caution in patients older than 75 years, due to the greater potential for adverse events in this population (see WARNINGS AND PRECAUTIONS, DOSAGE AND ADMINISTRATION).
Pediatrics ( < 18 Years of Age)
The safety and effectiveness of Orozamudol® have not been studied in the pediatric population. Therefore, use of Orozamudol® tablets is not recommended in patients under 18 years of age.